SK bioscience Co.,Ltd. (KRX:302440)

South Korea flag South Korea · Delayed Price · Currency is KRW
50,300
-1,000 (-1.95%)
Last updated: Jun 23, 2025
1.93%
Market Cap 3.76T
Revenue (ttm) 399.83B
Net Income (ttm) -47.63B
Shares Out 78.37M
EPS (ttm) -613.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 247,005
Average Volume 206,125
Open 49,900
Previous Close 51,300
Day's Range 48,450 - 50,600
52-Week Range 35,800 - 61,500
Beta 1.22
RSI 58.03
Earnings Date Aug 12, 2025

About SK bioscience

SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical tr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 984
Stock Exchange Korea Stock Exchange
Ticker Symbol 302440
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.